Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Spironolactone for Paroxysmal Atrial Fibrillation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00689598
Recruitment Status : Unknown
Verified June 2008 by Taichung Veterans General Hospital.
Recruitment status was:  Recruiting
First Posted : June 3, 2008
Last Update Posted : June 5, 2008
Sponsor:
Information provided by:
Taichung Veterans General Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
To determine whether or not spironolactone can prevent or delay the occurrence of atrial fibrillation.

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Drug: Spironolactone Drug: Placebo Not Applicable

Detailed Description:
To determine whether or not adding spironolactone can prevent or delay the occurrence of paroxysmal atrial fibrillation in patients who have received propafenone treatment.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Use of Spironolactone to Treat Patients With Paroxysmal Atrial Fibrillation- A Multi-Center, Prospective, Randomized, Placebo-Controlled, Double Blind Study
Study Start Date : March 2008
Estimated Primary Completion Date : March 2011
Estimated Study Completion Date : March 2011

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Placebo Comparator: III
Placebo
 Drug: Spironolactone
25 mg po qd 25 mg po bid
Other Name: Aldactone
Experimental: Experimental
Drug intervention
 Drug: Spironolactone
25 mg po qd 25 mg po bid
Other Name: Aldactone

Drug: Placebo
Spironolactone 25 mg po qd
Other Name: Aldactone


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. time to a first electrocardiographically confirmed AF [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. 1. Response rate: Improvement of any symptom scores and/or SF36 scores more than 50 % (compared with re-randomization scores) 2. Difference of mean episodes of documented AF between the spironolactone and placebo groups. [ Time Frame: 3 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. 18 to 80 Y/O,
  2. Paroxysmal AF.

Exclusion criteria:

  1. GPT>100 IU/L or tota bilirubin >2 mg/dl;
  2. Creatinine > 2 mg/dl;
  3. Serum potassium >= 5 mM;
  4. Serum sodium <=130 mM;
  5. Uric acid > 10 mg/dl。
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00689598


Contacts
Layout table for location contacts
Contact: Tsu-Juey Wu, M.D. 886-4-23592525 ext 4043 tjwu@vghtc.vghtc.gov.tw

Locations
Layout table for location information
Taiwan
Taichung General Hospital Recruiting
Taichung, Taiwan, 40705
Contact: Tsu-Juey Wu, M.D.    886-4-23592525 ext 4043    tjwu@vghtc.vghtc.gov.tw   
Sponsors and Collaborators
Taichung Veterans General Hospital
Investigators
Layout table for investigator information
Principal Investigator: Tsu-Juey Wu, M.D. TCVGH
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: Tsu-Juey Wu, M.D./Staff Physician, Taichung Veterans General Hospital
ClinicalTrials.gov Identifier: NCT00689598    
Other Study ID Numbers: C07061
First Posted: June 3, 2008    Key Record Dates
Last Update Posted: June 5, 2008
Last Verified: June 2008
Keywords provided by Taichung Veterans General Hospital:
Atrial fibrillation, spironolactone
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Spironolactone
Mineralocorticoid Receptor Antagonists
 Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Diuretics
Natriuretic Agents